News
Lawley Pharmaceuticals foundation Member of 7 year CRC Mental Health initiative.
Michael Buckley of Lawley Pharmaceuticalsat the CRC Launch
The $70 million nationwide joint Australian Government and Industry Co-operative Research Centre (CRC) for Mental Health was officially launched by Senator Kim Carr on Thursday 17 November 2011 in Melbourne and in Perth on Thursday 24th November 2011 by the Governor of Western Australia His Excellency Sir Malcolm McCusker.
The CRC for Mental Health researches early detection and treatment of neurodegenerative diseases and psychoses. The CRC’s research includes areas such as Alzheimer’s and Parkinson’s Disease and psychoses such as schizophrenia and mood disorders.
Video: CRC for Mental Health
» Learn more about the CRC for Mental Health.
CRC Mental Health – Testosterone and Alzheimer’s Disease landmark study.
In a world first study the hormone testosterone will be evaluated as a treatment option for Alzheimer’s disease in a human clinical trial as part of the national CRC for Mental Health initiative recently launched Australia-wide in November 2011.
The study to be conducted by Professor Ralph Martins at the McCusker Foundation for Alzheimers Research in Perth, Australia will examine the responsiveness of male patients with early phase symptoms of Alzheimer’s Disease. In animal studies testosterone has been shown to significantly reduce the accumulation of the toxic protein beta-amyloid in the brain which is characteristic of Alzheimer’s Disease sufferers.
Researchers believe that testosterone may be the key to removing the accumulation of beta-amyloid in the brain Alzheimer’s patients and improve quality of life for thousands of patients and their families. It is expected that by 2050 Australia will have 1.13 million people affected by Alzheimer’s Disease.
Lawley Pharmaceuticals as a member of the CRC for Mental Health is at the forefront of this research and has for many years worked closely with Professor Martins and his team.
The study is expected to get underway in the second half of 2012. For further details please contact www.alzheimers.com.au